Beraprost Sodium 314d Modified Release Tablets ( DrugBank: Beraprost )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,181 /  Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01908699 (ClinicalTrials.gov)	May 31, 2013	16/7/2013	Beraprost-314d Added-on to Tyvaso® (BEAT)	A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Beraprost Sodium 314d Modified Release Tablets;Drug: Placebo	Lung Biotechnology PBC	NULL	Completed	18 Years	80 Years	All	273	Phase 3	United States;Israel
2	NCT01458236 (ClinicalTrials.gov)	November 2011	29/9/2011	A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor	A Multinational, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor	Pulmonary Arterial Hypertension	Drug: Beraprost Sodium 314d Modified Release Tablets;Drug: Placebo	Lung Biotechnology Inc.	NULL	Withdrawn	18 Years	80 Years	Both	0	Phase 3	NULL